Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Aura Biosciences Inc (AURA)

Aura Biosciences Inc (AURA)
5.40 x 5 6.07 x 1
Post-market by (Cboe BZX)
5.52 +0.09 (+1.66%) 04/07/25 [NASDAQ]
5.40 x 5 6.07 x 1
Post-market 5.63 +0.11 (+1.99%) 16:02 ET
Quote Overview for Mon, Apr 7th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
5.07
Day High
5.55
Open 5.30
Previous Close 5.43 5.43
Volume 321,224 321,224
Avg Vol 458,576 458,576
Stochastic %K 10.68% 10.68%
Weighted Alpha -47.71 -47.71
5-Day Change -0.34 (-5.80%) -0.34 (-5.80%)
52-Week Range 5.07 - 12.38 5.07 - 12.38
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 272,722
  • Shares Outstanding, K 50,225
  • Annual Sales, $ 0 K
  • Annual Income, $ -86,920 K
  • EBIT $ -96 M
  • EBITDA $ -95 M
  • 60-Month Beta 0.43
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.88

Options Overview Details

View History
  • Implied Volatility 210.20% ( +31.13%)
  • Historical Volatility 68.85%
  • IV Percentile 86%
  • IV Rank 69.61%
  • IV High 293.28% on 02/03/25
  • IV Low 19.94% on 10/09/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 13
  • Put/Call OI Ratio 0.44
  • Today's Open Interest 245
  • Open Int (30-Day) 206

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.45
  • Number of Estimates 3
  • High Estimate -0.43
  • Low Estimate -0.49
  • Prior Year -0.40
  • Growth Rate Est. (year over year) -12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.07 +8.88%
on 04/07/25
Period Open: 7.40
7.73 -28.59%
on 03/24/25
-1.88 (-25.41%)
since 03/07/25
3-Month
5.07 +8.88%
on 04/07/25
Period Open: 8.08
8.27 -33.25%
on 02/06/25
-2.56 (-31.68%)
since 01/07/25
52-Week
5.07 +8.88%
on 04/07/25
Period Open: 7.20
12.38 -55.41%
on 10/18/24
-1.68 (-23.33%)
since 04/05/24

Most Recent Stories

More News
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors

AURA : 5.52 (+1.66%)
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

AURA : 5.52 (+1.66%)
Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress

AURA : 5.52 (+1.66%)
Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress

AURA : 5.52 (+1.66%)
Aura Biosciences to Participate in Upcoming Investor Conferences

AURA : 5.52 (+1.66%)
Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference

AURA : 5.52 (+1.66%)
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights

AURA : 5.52 (+1.66%)
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial

AURA : 5.52 (+1.66%)
3 Small-Cap Stocks Ready to Deliver Significant Growth

Small-cap firms will have an easier time borrowing money for growth in a lower-interest-rate environment; these are a few companies poised for a breakout.

TZOO : 11.68 (+1.30%)
AURA : 5.52 (+1.66%)
FBRT : 11.36 (-4.70%)
Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights

Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial...

AURA : 5.52 (+1.66%)

Business Summary

Aura Biosciences Inc. is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system. The company's lead product candidate includes AU-011. Aura Biosciences Inc. is based...

See More

Key Turning Points

3rd Resistance Point 6.15
2nd Resistance Point 5.94
1st Resistance Point 5.69
Last Price 5.52
1st Support Level 5.23
2nd Support Level 5.02
3rd Support Level 4.77

See More

52-Week High 12.38
Fibonacci 61.8% 9.59
Fibonacci 50% 8.72
Fibonacci 38.2% 7.86
Last Price 5.52
52-Week Low 5.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades